✉ Email this page to a colleague
« Back to Dashboard
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for CERIANNA
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for CERIANNA
CERIANNA is protected by zero US patents and one FDA Regulatory Exclusivity.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of CERIANNA is ⤷ Try a Trial.
This potential generic entry date is based on NEW CHEMICAL ENTITY.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
FDA Regulatory Exclusivity protecting CERIANNA
NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷ Try a Trial
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||TE||Type||RLD||RS||Patent No.||Patent Expiration||Product||Substance||Delist Req.||Exclusivity Expiration|
|Ge Healthcare||CERIANNA||fluoroestradiol f-18||SOLUTION;INTRAVENOUS||212155-001||May 20, 2020||RX||Yes||Yes||⤷ Try a Trial||⤷ Try a Trial||⤷ Try a Trial|
|>Applicant||>Tradename||>Generic Name||>Dosage||>NDA||>Approval Date||>TE||>Type||>RLD||>RS||>Patent No.||>Patent Expiration||>Product||>Substance||>Delist Req.||>Exclusivity Expiration|